National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) in combination with axitinib (Inlyta®) for 1L RCC. HTA ID: 19027

Pembrolizumab (Keytruda®), in combination with axitinib (Inlyta®), is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.

NCPE Assessment Process Complete
Rapid review commissioned 29/07/2019
Rapid review completed 23/08/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with axitinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/08/2019
Pre-submission consultation with Applicant 16/09/2019
Submission received from Applicant 07/05/2020
Preliminary review sent to Applicant 06/07/2020
NCPE assessment re-commenced 20/08/2020
Factual accuracy check sent to Applicant 01/12/2020
NCPE assessment re-commenced 08/12/2020
NCPE assessment completed 21/12/2020
Current status The NCPE recommends that pembrolizumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. *

Technical Summary

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 201